Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Measures to predict and prevent carbon monoxide poisoning after storm

Severe weather events, such as summer hurricanes, tornadoes, and winter snow storms often result in widespread and prolonged power outages, interrupting essential household functions, including home heating.

27 Sep 2018

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

American Cancer Society releases new cookbook for cancer patients

The American Cancer Society will release the second edition of What to Eat During Cancer Treatment on Oct. 1.

26 Sep 2018

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

A Special Focus Issue on Integrative Oncology takes a wide-ranging view of the possible approaches and potential therapeutic benefits of complementary and integrative medicine in multiple age groups, nations, and special populations.

25 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

$CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL$

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

AbbVie, a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for VENCLYXTO® in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who have received at least one prior therapy.

21 Sep 2018

Study offers solid link between visceral organs and brain’s reward, motivation system

A novel gut-to-brain neural circuit establishes the vagus nerve as an essential component of the brain system that regulates reward and motivation, according to research conducted at the Icahn School of Medicine at Mount Sinai and published September 20 in the journal Cell.

21 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018

Leading nutritionist explains about different types of iron in oral supplements

Iron is the top nutritional deficiency in the world, as many as 80 percent of people do not have enough iron in their body according to the World Health Organization.

From BetterYou Ltd 19 Sep 2018

Day-tripping to the dispensary: Seniors in pain hop aboard the canna-bus

Shirley Avedon, 90, had never been a cannabis user. But carpal tunnel syndrome that sends shooting pains into both of her hands and an aversion to conventional steroid and surgical treatments is prompting her to consider some new options.

18 Sep 2018

UNC Health Care extends free access to virtual care service in the aftermath of Hurricane Florence

In the aftermath of Hurricane Florence and continued challenging conditions across much of the state, UNC Health Care has extended its offer of free access to its virtual care service, UNC Urgent Care 24/7

18 Sep 2018

Targeted Lung Denervation procedure significantly reduces COPD problems

First results from a clinical trial of a procedure to open obstructed airways in patients with chronic obstructive pulmonary disease have shown that it significantly reduces problems associated with the disease and is safe.

18 Sep 2018

Half as many people are trying heroin, but marijuana use grows

Some good news from the front lines of the heroin crisis: Half as many people tried heroin for the first time in 2017 as in 2016. That's according to data released Friday from the government's annual National Survey on Drug Use and Health.

14 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Nausea News and Research

Further Reading

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Measures to predict and prevent carbon monoxide poisoning after storm

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

American Cancer Society releases new cookbook for cancer patients

Special Focus Issue takes wide view of complementary and integrative medicine in cancer

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Study offers solid link between visceral organs and brain’s reward, motivation system

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Leading nutritionist explains about different types of iron in oral supplements

Day-tripping to the dispensary: Seniors in pain hop aboard the canna-bus

UNC Health Care extends free access to virtual care service in the aftermath of Hurricane Florence

Targeted Lung Denervation procedure significantly reduces COPD problems

Half as many people are trying heroin, but marijuana use grows

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News